...
首页> 外文期刊>BMC Cancer >Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)–a comparison between 2004-2006 and 2007-2009
【24h】

Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)–a comparison between 2004-2006 and 2007-2009

机译:奈良Uro肿瘤研究小组(NUORG)对日本前列腺癌患者进行风险分类和主要治疗的趋势– 2004-2006年与2007-2009年之间的比较

获取原文
           

摘要

Background To assess the trends of risk classification and primary therapy in Japanese patients who were diagnosed with prostate cancer between 2004-2006 and 2007-2009. Methods A total of 4752 patients who were newly diagnosed with prostate cancer at Nara Medical University and its 23 affiliated hospitals between 2004 and 2009 were enrolled. The differences in risk classification and primary therapy were compared in patients who were newly diagnosed between 2004-2006 (prior period) and 2007-2009 (latter period). Results The proportion of patients with a high or greater risk significantly decreased in the latter period compared to the prior period (p Conclusions Higher risk patients significantly decreased in the latter period compared to the prior period. The use of PADT also significantly decreased in the latter period. However, there were still higher risk patients in Japan, and the use of PADT was still common in patients with localized prostate cancer or locally advanced prostate cancer in Japan.
机译:背景为了评估在2004-2006年至2007-2009年间被诊断患有前列腺癌的日本患者的风险分类和主要疗法的趋势。方法收集2004年至2009年间在奈良医科大学及其23家附属医院新诊断为前列腺癌的4752例患者。比较了2004-2006年(先前期)和2007-2009年(后期)之间新诊断的患者的风险分类和主要疗法的差异。结果与上一时期相比,后期高危或高危患者的比例显着下降(p结论高一例中,高危患者与上一时期相比显着下降。PADT的使用在后一时期也显着减少然而,在日本,仍然有较高风险的患者,并且在日本局部前列腺癌或局部晚期前列腺癌的患者中仍普遍使用PADT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号